|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We show that a highly aggressive subclone of murine BCL-1 B-lineage leukemia expresses a single 2.4-kb transcript hybridizing to the human CD19 cDNA probe and reacts strongly with the anti-human CD19 monoclonal antibodies (MoAb) B43, B4, Leu-12, and J3-119.
|
1375109 |
1992 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD19 represents an attractive immunotherapy target for cancers of lymphoid origin due to its high expression levels on the vast majority of non-Hodgkin's lymphomas and some leukemias.
|
18829563 |
2008 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.
|
29451276 |
2017 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We retrospectively analyzed 65 patients with refractory/relapsed (r/r) ALL who were treated with blinatumomab for predictors of leukemia response as well as clinical patterns of relapse and resistance with particular focus on downregulation of CD19 expression and extramedullary disease (EM-ALL).
|
28494518 |
2017 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our study suggests that KIT activating mutations in AML with t(8; 21) are associated with diminished CD 19 and positive CD56 expression on leukemic blasts and, thus, can be phenotypically distinguished from AML1-ETO leukemias without KIT mutations.
|
17875504 |
2007 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.
|
12393484 |
2003 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
An anti-CD19 chimeric receptor for the targeting of leukemias and lymphomas was used as a model system.
|
20387166 |
2010 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel therapies with chimeric antigen receptor (CAR)-transduced T cells (TCs) sparked new hope for patients with relapsed or refractory CD19-positive leukemia or lymphoma even after stem cell therapies.
|
27479233 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed a preclinical validation using a model of CD33<sup>+</sup> AML, and generated iC9 CAR T-cells co-expressing a CAR targeting the AML-associated antigen CD33 and a selectable marker (ΔCD19).ΔCD19 selected (sel.) iC9-CAR.CD33 T-cells were effective in controlling leukemia growth in vitro, and could be partially eliminated (76%) using a chemical inducer of dimerization that activates iC9.
|
30539529 |
2019 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.
|
30733273 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Four hematological groups could be distinguished: (i) 13 cases of acute lymphoblastic leukemia (ALL) of B lineage, mostly CD19+; (ii) eight cases of biphenotypic leukemia: CD19+ (most often) ALL but with simultaneous or inducible expression of differentiation marker of monocytic lineage.
|
8426468 |
1993 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Such incongruity was also observed in t(4;11) patients in whom leukemia evaded CD19-directed therapy by undergoing myeloid-lineage switch.
|
27846391 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this murine model, we identified a new, Rag1-independent leukemia-initiating mechanism originating from a Sca1(+)CD19(+) precursor cell population and showed that Notch1 expression accelerates the cells' self-renewal capacity in vitro.
|
21622646 |
2011 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MP1-specific CTLs are amenable to subsequent genetic modification to express a CD19-specific CAR, designated CD19R, and acquire HLA-unrestricted reactivity toward CD19(+) leukemia and lymphoma tumor targets while maintaining HLA-restricted MP1 specificity.
|
15507526 |
2005 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
During this treatment, the leukemia lost CD19 expression as well as nearly all other B-cell markers, while still harboring the initial minimal residual disease marker, and switched to a myeloid phenotype.
|
28453885 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this regard, CD19-specific CAR T cell therapies have achieved dramatic objective responses for a high percent of patients with CD19-positive leukemia or lymphoma.
|
30828333 |
2019 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The targeting of CD19, a cell surface molecule expressed in the vast majority of leukemias and lymphomas, has been successfully translated in the clinic, earning CAR therapy a special distinction in the selection of "cancer immunotherapy" by Science as the breakthrough of the year in 2013.
|
28456379 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.
|
23233573 |
2012 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunophenotyping of the first leukemia sample revealed a mixed lineage leukemia immunophenotype with positivity for terminal deoxynucleotidyl transferase (TdT), CD13 and CD19; the second sample revealed solely myeloid characteristics with positivity for CD13, CD41 and CD61, whereas TdT was negative.
|
15863212 |
2005 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In one case a bilineage leukemia with a POEM+/CD 19- and a POEM-/CD 19+ population could be identified by immunoelectron microscopical studies (IEM).
|
7920215 |
1994 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we compared CD19 bispecific T-cell engager (BiTE)-transferred T cells that had been transfected by RNA electroporation with CD19 CAR RNA-transferred T cells both in vitro and in an aggressive Nalm6 leukemia mouse model.
|
27258611 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that T cells genetically modified with a replication-defective gammaretroviral vector derived from the Moloney murine leukemia virus encoding a chimeric antigen receptor (CAR) targeted to CD19 (1928z) can be expanded with Dynabeads CD3/CD28.
|
19238016 |
2009 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The incidence of leukemia in these mice varied from 5% to 50%, dependent on the Cre-driving promoter (Cd19, Mb1, or Mx1) used to induce E2A-PBX1 expression.
|
26301816 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Return of CD19+ leukemia was associated with loss of CAR T-cell function, whereas CD19- leukemia was associated with continued CAR T-cell function.
|
31738832 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Short TSLPR CAR treatment of mice engrafted with a TSLPR-expressing ALL cell line induced leukemia cytotoxicity with efficacy comparable with that of CD19 CAR T cells.
|
26041741 |
2015 |